Michelle M. Butler
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2014First federal award
$9.9MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $9.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 17, 2021 | NIH | SBIR Phase II Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | $997K | MICROBIOTIX, INC. |
| Dec 15, 2020 | NIH | SBIR Phase II Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | $982K | MICROBIOTIX, INC. |
| Sep 3, 2020 | NIH | SBIR Phase II Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | $1.0M | MICROBIOTIX, INC. |
| Nov 26, 2019 | NIH | SBIR Phase II Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | $992K | MICROBIOTIX, INC. |
| Aug 21, 2019 | NIH | SBIR Phase II Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | $1000K | MICROBIOTIX, INC. |
| Dec 13, 2018 | NIH | SBIR Phase II Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | $1000K | MICROBIOTIX, INC. |
| Jul 19, 2018 | NIH | SBIR Phase I Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs | $289K | MICROBIOTIX, INC. |
| Aug 18, 2017 | NIH | SBIR Phase I Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs | $297K | MICROBIOTIX, INC. |
| May 9, 2016 | NIH | SBIR Phase II Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis | $982K | MICROBIOTIX, INC. |
| Dec 21, 2015 | NIH | SBIR Phase II Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | $690K | MICROBIOTIX, INC. |
| Apr 27, 2015 | NIH | SBIR Phase II Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis | $988K | MICROBIOTIX, INC. |
| Dec 16, 2014 | NIH | SBIR Phase II Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | $644K | MICROBIOTIX, INC. |
Peer ranks
Federal funding#62
Awards as PI#86
Patents#273
Companies
- MICROBIOTIX, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.